---
title: "Coimbra Protocol (using Vitamin D) is safe and effective for Multiple Sclerosis and Autoimmune diseases"
slug: "coimbra-protocol-using-vitamin-d-is-safe-and-effective-for-multiple-sclerosis-an-immune-diseases"
aliases:
  - "/Coimbra+Protocol+using+Vitamin+D+is+safe+and+effective+for+Multiple+Sclerosis+and+Autoimmune+diseases+–+April+2022"
  - "/15435"
tiki_page_id: 15435
date: 2024-08-01
---


{{< toc >}}

---

#### Safety Data in Patients with Autoimmune Diseases during Treatment with High Doses of Vitamin D3 According to the “Coimbra Protocol”

Nutrients 2022, 14(8), 1575; https://doi.org/10.3390/nu14081575

Ulrich Amon 1,*ORCID,Raul Yaguboglu 1,Madeleine Ennis 2, Michael F. Holick 3 ORCID and Julian Amon 1ORCID

* 1 International Centre for Skin Diseases DermAllegra,  **Coimbra Protocol Certified Center** , Am Markgrafenpark 6, 91224 Pommelsbrunn-Hohenstadt, Germany

* 2 The Wellcome-Wolfson Institute for Experimental Medicine, Queens University of Belfast, Belfast BT7 1NN, UK

* 3 Endocrinology, Diabetes, Nutrition & Weight Management, Dept. of Medicine, Boston University School of Medicine, Boston, MA 02118, USA

<img src="https://d1bk1kqxc0sym.cloudfront.net/attachments/webp/autoimmune-table.webp" alt="image" width="400">

<img src="https://d1bk1kqxc0sym.cloudfront.net/attachments/webp/pth-vs-time.webp" alt="image" width="500"> 

<img src="https://d1bk1kqxc0sym.cloudfront.net/attachments/webp/dose-vs-time.webp" alt="image" width="500">

Background: In 2013, the group of Cicero Coimbra, Brazil, reported the clinical efficacy of high doses of vitamin D3 in patients suffering from autoimmune skin disorders (“Coimbra protocol”, CP). However, hypercalcemia and the subsequent impaired renal function may be major concerns raised against this protocol. 

Methods: We report for the first time for a broad spectrum of autoimmune diseases in 319 patients (mean age (±SD) 43.3 ± 14.6 years, 65.5% female, 34.5% male) safety data for high doses of orally applied vitamin D3 (treatment period: up to 3.5 years) accompanied by a strict low-calcium diet and regular daily fluid intake of at least 2.5 L. 

Results: Mean vitamin D3 dose was 35,291 ± 21,791 IU per day. The measurement of more than 6100 single relevant laboratory parameters showed all mean values (±SD) within the normal range for total serum calcium (2.4 ± 0.1 mmol/L), serum creatinine (0.8 ± 0.2 mg/dL), serum creatinine associated estimated GFR (92.5 ± 17.3 mL/min), serum cystatin C (0.88 ± 0.19 mg/L), serum TSH (1.8 ± 1 mIU/L), and for 24 h urinary calcium secretion (6.9 ± 3.3 mmol/24 h). We found a very weak relationship between the dosage of oral vitamin D3 and the subsequent calcium levels, both in serum and in urinary excretion over 24 h, respectively. 

Conclusions: Our data show the reliable safety of the CP in autoimmune patients under appropriate supervision by experienced physicians.

 **<i class="fas fa-file-pdf" style="margin-right: 0.3em;"></i><a href="https://d1bk1kqxc0sym.cloudfront.net/attachments/pdf/-coimbra-protocol-autoimmune-compresspdf.pdf">Download the PDF from VitaminDWiki </a>** 

<img src="https://d1bk1kqxc0sym.cloudfront.net/attachments/webp/snp-cp.webp" alt="image" width="500">

75% had mutations in the genes encoding the enzymes CYP2R1 and CYP27B1 

74% has 4+ mutations in nine different genes 

5% had mutations in all genes investigated

---

#### Coimbra protocol appears to have not tried 8+ things

1. Infrequent dosing, perhaps once every 3 days - a good way to get past the VDR

1. Activation of Vitamin D receptors by Resveratrol and 14 other methods

1. Glutathione etc, which activate many vitamin D genes

1. Other forms of Vitamin D – which are more bioavailable – especially if poor gut

1. The use of probiotics to improve the gut microbiome

1. Water-soluble Vitamin D, Omega-3 - so that fat is not required concurrently 

1. Loading dose to speedup the treatment by several months

1. Plant-based Calcium for those who must have Calcium


<pre style="background-color: #e0e0e0; white-space: pre-wrap;">
<code class="language-text">
Markdown:
--------
{{&lt; toc &gt;}}

---

#### Safety Data in Patients with Autoimmune Diseases during Treatment with High Doses of Vitamin D3 According to the “Coimbra Protocol”

Nutrients 2022, 14(8), 1575; https://doi.org/10.3390/nu14081575

Ulrich Amon 1,*ORCID,Raul Yaguboglu 1,Madeleine Ennis 2, Michael F. Holick 3 ORCID and Julian Amon 1ORCID

* 1 International Centre for Skin Diseases DermAllegra,  **Coimbra Protocol Certified Center** , Am Markgrafenpark 6, 91224 Pommelsbrunn-Hohenstadt, Germany

* 2 The Wellcome-Wolfson Institute for Experimental Medicine, Queens University of Belfast, Belfast BT7 1NN, UK

* 3 Endocrinology, Diabetes, Nutrition &amp; Weight Management, Dept. of Medicine, Boston University School of Medicine, Boston, MA 02118, USA

&lt;img src=&quot;https://d1bk1kqxc0sym.cloudfront.net/attachments/webp/autoimmune-table.webp&quot; alt=&quot;image&quot; width=&quot;400&quot;&gt;

&lt;img src=&quot;https://d1bk1kqxc0sym.cloudfront.net/attachments/webp/pth-vs-time.webp&quot; alt=&quot;image&quot; width=&quot;500&quot;&gt; 

&lt;img src=&quot;https://d1bk1kqxc0sym.cloudfront.net/attachments/webp/dose-vs-time.webp&quot; alt=&quot;image&quot; width=&quot;500&quot;&gt;

Background: In 2013, the group of Cicero Coimbra, Brazil, reported the clinical efficacy of high doses of vitamin D3 in patients suffering from autoimmune skin disorders (“Coimbra protocol”, CP). However, hypercalcemia and the subsequent impaired renal function may be major concerns raised against this protocol. 

Methods: We report for the first time for a broad spectrum of autoimmune diseases in 319 patients (mean age (±SD) 43.3 ± 14.6 years, 65.5% female, 34.5% male) safety data for high doses of orally applied vitamin D3 (treatment period: up to 3.5 years) accompanied by a strict low-calcium diet and regular daily fluid intake of at least 2.5 L. 

Results: Mean vitamin D3 dose was 35,291 ± 21,791 IU per day. The measurement of more than 6100 single relevant laboratory parameters showed all mean values (±SD) within the normal range for total serum calcium (2.4 ± 0.1 mmol/L), serum creatinine (0.8 ± 0.2 mg/dL), serum creatinine associated estimated GFR (92.5 ± 17.3 mL/min), serum cystatin C (0.88 ± 0.19 mg/L), serum TSH (1.8 ± 1 mIU/L), and for 24 h urinary calcium secretion (6.9 ± 3.3 mmol/24 h). We found a very weak relationship between the dosage of oral vitamin D3 and the subsequent calcium levels, both in serum and in urinary excretion over 24 h, respectively. 

Conclusions: Our data show the reliable safety of the CP in autoimmune patients under appropriate supervision by experienced physicians.

 **&lt;i class=&quot;fas fa-file-pdf&quot; style=&quot;margin-right: 0.3em;&quot;&gt;&lt;/i&gt;&lt;a href=&quot;https://d1bk1kqxc0sym.cloudfront.net/attachments/pdf/-coimbra-protocol-autoimmune-compresspdf.pdf&quot;&gt;Download the PDF from VitaminDWiki &lt;/a&gt;** 

&lt;img src=&quot;https://d1bk1kqxc0sym.cloudfront.net/attachments/webp/snp-cp.webp&quot; alt=&quot;image&quot; width=&quot;500&quot;&gt;

75% had mutations in the genes encoding the enzymes CYP2R1 and CYP27B1 

74% has 4+ mutations in nine different genes 

5% had mutations in all genes investigated

---

#### Coimbra protocol appears to have not tried 8+ things

1. Infrequent dosing, perhaps once every 3 days - a good way to get past the VDR

1. Activation of Vitamin D receptors by Resveratrol and 14 other methods

1. Glutathione etc, which activate many vitamin D genes

1. Other forms of Vitamin D – which are more bioavailable – especially if poor gut

1. The use of probiotics to improve the gut microbiome

1. Water-soluble Vitamin D, Omega-3 - so that fat is not required concurrently 

1. Loading dose to speedup the treatment by several months

1. Plant-based Calcium for those who must have Calcium


AST Structure:
-------------
├── DivNode
│   full_match: `{DIV(class=&quot;lefth4&quot;)}{maketoc Title=&quot;&quot;}{DIV}`
│   inner_content: `{maketoc Title=&quot;&quot;}`
│   attrs_dict:
│   │   raw_content: (class=&quot;lefth4&quot;)
│   │   class: lefth4
│   children:
│   ├── MakeTocNode
│   │   full_match: `{maketoc Title=&quot;&quot;}`
│   │   inner_content: ``
│   │   attrs_dict:
│   │   │   raw_content:  Title=&quot;&quot;
│   │   │   Title: ├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!Safety Data in Patients with Autoimmune Diseases during Treatment with High Doses of Vitamin D3 According to the “Coimbra Protocol”`
│   inner_content: `Safety Data in Patients with Autoimmune Diseases during Treatment with High Doses of Vitamin D3 According to the “Coimbra Protocol”`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `Safety Data in Patients with Autoimmune Diseases during Treatment with High Doses of Vitamin D3 According to the “Coimbra Protocol”`
│   │   inner_content: `Safety Data in Patients with Autoimmune Diseases during Treatment with High Doses of Vitamin D3 According to the “Coimbra Protocol”`├── TextNode
│   full_match: `\nNutrients 2022, 14(8), 1575; https://doi.org/10.3390/nu14081575\nUlrich Amon 1,*ORCID,Raul Yaguboglu 1,Madeleine Ennis 2, Michael F. Holick 3 ORCID and Julian Amon 1ORCID\n`
│   inner_content: `\nNutrients 2022, 14(8), 1575; https://doi.org/10.3390/nu14081575\nUlrich Amon 1,*ORCID,Raul Yaguboglu 1,Madeleine Ennis 2, Michael F. Holick 3 ORCID and Julian Amon 1ORCID\n`├── ListItemNode
│   full_match: `*1 International Centre for Skin Diseases DermAllegra, __Coimbra Protocol Certified Center__, Am Markgrafenpark 6, 91224 Pommelsbrunn-Hohenstadt, Germany`
│   inner_content: `1 International Centre for Skin Diseases DermAllegra, __Coimbra Protocol Certified Center__, Am Markgrafenpark 6, 91224 Pommelsbrunn-Hohenstadt, Germany`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `1 International Centre for Skin Diseases DermAllegra, `
│   │   inner_content: `1 International Centre for Skin Diseases DermAllegra, `
│   ├── BoldNode
│   │   full_match: `__Coimbra Protocol Certified Center__`
│   │   inner_content: `Coimbra Protocol Certified Center`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Coimbra Protocol Certified Center`
│   │   │   inner_content: `Coimbra Protocol Certified Center`
│   ├── TextNode
│   │   full_match: `, Am Markgrafenpark 6, 91224 Pommelsbrunn-Hohenstadt, Germany`
│   │   inner_content: `, Am Markgrafenpark 6, 91224 Pommelsbrunn-Hohenstadt, Germany`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*2 The Wellcome-Wolfson Institute for Experimental Medicine, Queens University of Belfast, Belfast BT7 1NN, UK`
│   inner_content: `2 The Wellcome-Wolfson Institute for Experimental Medicine, Queens University of Belfast, Belfast BT7 1NN, UK`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `2 The Wellcome-Wolfson Institute for Experimental Medicine, Queens University of Belfast, Belfast BT7 1NN, UK`
│   │   inner_content: `2 The Wellcome-Wolfson Institute for Experimental Medicine, Queens University of Belfast, Belfast BT7 1NN, UK`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*3 Endocrinology, Diabetes, Nutrition &amp; Weight Management, Dept. of Medicine, Boston University School of Medicine, Boston, MA 02118, USA`
│   inner_content: `3 Endocrinology, Diabetes, Nutrition &amp; Weight Management, Dept. of Medicine, Boston University School of Medicine, Boston, MA 02118, USA`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `3 Endocrinology, Diabetes, Nutrition &amp; Weight Management, Dept. of Medicine, Boston University School of Medicine, Boston, MA 02118, USA`
│   │   inner_content: `3 Endocrinology, Diabetes, Nutrition &amp; Weight Management, Dept. of Medicine, Boston University School of Medicine, Boston, MA 02118, USA`├── TextNode
│   full_match: `\n\n`
│   inner_content: `\n\n`├── ImgNode
│   full_match: `{img type=&quot;attId&quot; attId=&quot;21487&quot; width=&quot;400&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  type=&quot;attId&quot; attId=&quot;21487&quot; width=&quot;400&quot;
│   │   type: attId
│   │   attId: 21487
│   │   width: 400├── TextNode
│   full_match: `\n\n`
│   inner_content: `\n\n`├── ImgNode
│   full_match: `{img type=&quot;attId&quot; attId=&quot;21488&quot; width=&quot;500&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  type=&quot;attId&quot; attId=&quot;21488&quot; width=&quot;500&quot;
│   │   type: attId
│   │   attId: 21488
│   │   width: 500├── TextNode
│   full_match: ` \n\n`
│   inner_content: ` \n\n`├── ImgNode
│   full_match: `{img type=&quot;attId&quot; attId=&quot;21489&quot; width=&quot;500&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  type=&quot;attId&quot; attId=&quot;21489&quot; width=&quot;500&quot;
│   │   type: attId
│   │   attId: 21489
│   │   width: 500├── TextNode
│   full_match: `\nBackground: In 2013, the group of Cicero Coimbra, Brazil, reported the clinical efficacy of high doses of vitamin D3 in patients suffering from autoimmune skin disorders (“Coimbra protocol”, CP). However, hypercalcemia and the subsequent impaired renal function may be major concerns raised against this protocol. \n\nMethods: We report for the first time for a broad spectrum of autoimmune diseases in 319 patients (mean age (±SD) 43.3 ± 14.6 years, 65.5% female, 34.5% male) safety data for high doses of orally applied vitamin D3 (treatment period: up to 3.5 years) accompanied by a strict low-calcium diet and regular daily fluid intake of at least 2.5 L. \n\nResults: Mean vitamin D3 dose was 35,291 ± 21,791 IU per day. The measurement of more than 6100 single relevant laboratory parameters showed all mean values (±SD) within the normal range for total serum calcium (2.4 ± 0.1 mmol/L), serum creatinine (0.8 ± 0.2 mg/dL), serum creatinine associated estimated GFR (92.5 ± 17.3 mL/min), serum cystatin C (0.88 ± 0.19 mg/L), serum TSH (1.8 ± 1 mIU/L), and for 24 h urinary calcium secretion (6.9 ± 3.3 mmol/24 h). We found a very weak relationship between the dosage of oral vitamin D3 and the subsequent calcium levels, both in serum and in urinary excretion over 24 h, respectively. \n\nConclusions: Our data show the reliable safety of the CP in autoimmune patients under appropriate supervision by experienced physicians.\n`
│   inner_content: `\nBackground: In 2013, the group of Cicero Coimbra, Brazil, reported the clinical efficacy of high doses of vitamin D3 in patients suffering from autoimmune skin disorders (“Coimbra protocol”, CP). However, hypercalcemia and the subsequent impaired renal function may be major concerns raised against this protocol. \n\nMethods: We report for the first time for a broad spectrum of autoimmune diseases in 319 patients (mean age (±SD) 43.3 ± 14.6 years, 65.5% female, 34.5% male) safety data for high doses of orally applied vitamin D3 (treatment period: up to 3.5 years) accompanied by a strict low-calcium diet and regular daily fluid intake of at least 2.5 L. \n\nResults: Mean vitamin D3 dose was 35,291 ± 21,791 IU per day. The measurement of more than 6100 single relevant laboratory parameters showed all mean values (±SD) within the normal range for total serum calcium (2.4 ± 0.1 mmol/L), serum creatinine (0.8 ± 0.2 mg/dL), serum creatinine associated estimated GFR (92.5 ± 17.3 mL/min), serum cystatin C (0.88 ± 0.19 mg/L), serum TSH (1.8 ± 1 mIU/L), and for 24 h urinary calcium secretion (6.9 ± 3.3 mmol/24 h). We found a very weak relationship between the dosage of oral vitamin D3 and the subsequent calcium levels, both in serum and in urinary excretion over 24 h, respectively. \n\nConclusions: Our data show the reliable safety of the CP in autoimmune patients under appropriate supervision by experienced physicians.\n`├── FontNode
│   full_match: `{FONT(size=&quot;17&quot;)}__{ATTACH(inline=&quot;1&quot; id=&quot;21486&quot; icon=&quot;1&quot;)}Download the PDF from VitaminDWiki {ATTACH}__{FONT}`
│   inner_content: `__{ATTACH(inline=&quot;1&quot; id=&quot;21486&quot; icon=&quot;1&quot;)}Download the PDF from VitaminDWiki {ATTACH}__`
│   attrs_dict:
│   │   raw_content: size=&quot;17&quot;
│   │   size: 17
│   children:
│   ├── BoldNode
│   │   full_match: `__{ATTACH(inline=&quot;1&quot; id=&quot;21486&quot; icon=&quot;1&quot;)}Download the PDF from VitaminDWiki {ATTACH}__`
│   │   inner_content: `{ATTACH(inline=&quot;1&quot; id=&quot;21486&quot; icon=&quot;1&quot;)}Download the PDF from VitaminDWiki {ATTACH}`
│   │   children:
│   │   ├── AttachNode
│   │   │   full_match: `{ATTACH(inline=&quot;1&quot; id=&quot;21486&quot; icon=&quot;1&quot;)}Download the PDF from VitaminDWiki {ATTACH}`
│   │   │   inner_content: `Download the PDF from VitaminDWiki `
│   │   │   attrs_dict:
│   │   │   │   raw_content: (inline=&quot;1&quot; id=&quot;21486&quot; icon=&quot;1&quot;)
│   │   │   │   inline: 1
│   │   │   │   id: 21486
│   │   │   │   icon: 1
│   │   │   children:
│   │   │   ├── TextNode
│   │   │   │   full_match: `Download the PDF from VitaminDWiki `
│   │   │   │   inner_content: `Download the PDF from VitaminDWiki `├── TextNode
│   full_match: `\n\n`
│   inner_content: `\n\n`├── ImgNode
│   full_match: `{img type=&quot;attId&quot; attId=&quot;21490&quot; width=&quot;500&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  type=&quot;attId&quot; attId=&quot;21490&quot; width=&quot;500&quot;
│   │   type: attId
│   │   attId: 21490
│   │   width: 500├── TextNode
│   full_match: `\n75% had mutations in the genes encoding the enzymes CYP2R1 and CYP27B1 \n74% has 4+ mutations in nine different genes \n5% had mutations in all genes investigated`
│   inner_content: `\n75% had mutations in the genes encoding the enzymes CYP2R1 and CYP27B1 \n74% has 4+ mutations in nine different genes \n5% had mutations in all genes investigated`├── HorizontalRuleAltNode
│   full_match: `\n----\n`
│   inner_content: `----`├── HeadingNode
│   full_match: `!!!!Coimbra protocol appears to have not tried 8+ things`
│   inner_content: `Coimbra protocol appears to have not tried 8+ things`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `Coimbra protocol appears to have not tried 8+ things`
│   │   inner_content: `Coimbra protocol appears to have not tried 8+ things`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Infrequent dosing, perhaps once every 3 days - a good way to get past the VDR`
│   inner_content: `Infrequent dosing, perhaps once every 3 days - a good way to get past the VDR`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Infrequent dosing, perhaps once every 3 days - a good way to get past the VDR`
│   │   inner_content: `Infrequent dosing, perhaps once every 3 days - a good way to get past the VDR`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Activation of Vitamin D receptors by Resveratrol and 14 other methods`
│   inner_content: `Activation of Vitamin D receptors by Resveratrol and 14 other methods`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Activation of Vitamin D receptors by Resveratrol and 14 other methods`
│   │   inner_content: `Activation of Vitamin D receptors by Resveratrol and 14 other methods`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Glutathione etc, which activate many vitamin D genes`
│   inner_content: `Glutathione etc, which activate many vitamin D genes`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Glutathione etc, which activate many vitamin D genes`
│   │   inner_content: `Glutathione etc, which activate many vitamin D genes`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Other forms of Vitamin D – which are more bioavailable – especially if poor gut`
│   inner_content: `Other forms of Vitamin D – which are more bioavailable – especially if poor gut`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Other forms of Vitamin D – which are more bioavailable – especially if poor gut`
│   │   inner_content: `Other forms of Vitamin D – which are more bioavailable – especially if poor gut`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#The use of probiotics to improve the gut microbiome`
│   inner_content: `The use of probiotics to improve the gut microbiome`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `The use of probiotics to improve the gut microbiome`
│   │   inner_content: `The use of probiotics to improve the gut microbiome`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Water-soluble Vitamin D, Omega-3 - so that fat is not required concurrently `
│   inner_content: `Water-soluble Vitamin D, Omega-3 - so that fat is not required concurrently `
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Water-soluble Vitamin D, Omega-3 - so that fat is not required concurrently `
│   │   inner_content: `Water-soluble Vitamin D, Omega-3 - so that fat is not required concurrently `├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Loading dose to speedup the treatment by several months`
│   inner_content: `Loading dose to speedup the treatment by several months`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Loading dose to speedup the treatment by several months`
│   │   inner_content: `Loading dose to speedup the treatment by several months`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Plant-based Calcium for those who must have Calcium`
│   inner_content: `Plant-based Calcium for those who must have Calcium`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Plant-based Calcium for those who must have Calcium`
│   │   inner_content: `Plant-based Calcium for those who must have Calcium`├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!VitaminDWiki – ((Overview MS and vitamin D)) contains `
│   inner_content: `VitaminDWiki – ((Overview MS and vitamin D)) contains`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki – `
│   │   inner_content: `VitaminDWiki – `
│   ├── LocalLinkNode
│   │   full_match: `((Overview MS and vitamin D))`
│   │   inner_content: `Overview MS and vitamin D`
│   │   page: `Overview MS and vitamin D`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Overview MS and vitamin D`
│   │   │   inner_content: `Overview MS and vitamin D`
│   ├── TextNode
│   │   full_match: ` contains`
│   │   inner_content: ` contains`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── IncludeNode
│   full_match: `{include page=&quot;Overview MS and vitamin D&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  page=&quot;Overview MS and vitamin D&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;
│   │   page: Overview MS and vitamin D
│   │   start: ~tc~ start ~/tc~
│   │   stop: ~tc~ end ~/tc~
│   children:
│   ├── TextNode
│   │   full_match: ``
│   │   inner_content: ``├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!VitaminDWiki – ((Multiple Sclerosis and (lots of) Vitamin D - book by patient on Coimbra protocol - Feb 2016)) contains protocol description__     `
│   inner_content: `VitaminDWiki – ((Multiple Sclerosis and (lots of) Vitamin D - book by patient on Coimbra protocol - Feb 2016)) contains protocol description__`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki – `
│   │   inner_content: `VitaminDWiki – `
│   ├── LocalLinkNode
│   │   full_match: `((Multiple Sclerosis and (lots of) Vitamin D - book by patient on Coimbra protocol - Feb 2016))`
│   │   inner_content: `Multiple Sclerosis and (lots of) Vitamin D - book by patient on Coimbra protocol - Feb 2016`
│   │   page: `Multiple Sclerosis and (lots of) Vitamin D - book by patient on Coimbra protocol - Feb 2016`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Multiple Sclerosis and (lots of) Vitamin D - book by patient on Coimbra protocol - Feb 2016`
│   │   │   inner_content: `Multiple Sclerosis and (lots of) Vitamin D - book by patient on Coimbra protocol - Feb 2016`
│   ├── TextNode
│   │   full_match: ` contains protocol description__`
│   │   inner_content: ` contains protocol description__`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── IncludeNode
│   full_match: `{include page=&quot;Multiple Sclerosis and (lots of) Vitamin D - book by patient on Coimbra protocol - Feb 2016&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  page=&quot;Multiple Sclerosis and (lots of) Vitamin D - book by patient on Coimbra protocol - Feb 2016&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;
│   │   page: Multiple Sclerosis and (lots of) Vitamin D - book by patient on Coimbra protocol - Feb 2016
│   │   start: ~tc~ start ~/tc~
│   │   stop: ~tc~ end ~/tc~
│   children:
│   ├── TextNode
│   │   full_match: ``
│   │   inner_content: ``├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!VitaminDWiki – ((Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019))`
│   inner_content: `VitaminDWiki – ((Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019))`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki – `
│   │   inner_content: `VitaminDWiki – `
│   ├── LocalLinkNode
│   │   full_match: `((Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019))`
│   │   inner_content: `Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019`
│   │   page: `Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019`
│   │   │   inner_content: `Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── IncludeNode
│   full_match: `{include page=&quot;Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  page=&quot;Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;
│   │   page: Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019
│   │   start: ~tc~ start ~/tc~
│   │   stop: ~tc~ end ~/tc~
│   children:
│   ├── TextNode
│   │   full_match: ``
│   │   inner_content: ``├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!VitaminDWiki – ((Psoriasis)) category contains`
│   inner_content: `VitaminDWiki – ((Psoriasis)) category contains`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki – `
│   │   inner_content: `VitaminDWiki – `
│   ├── LocalLinkNode
│   │   full_match: `((Psoriasis))`
│   │   inner_content: `Psoriasis`
│   │   page: `Psoriasis`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Psoriasis`
│   │   │   inner_content: `Psoriasis`
│   ├── TextNode
│   │   full_match: ` category contains`
│   │   inner_content: ` category contains`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── IncludeNode
│   full_match: `{include page=&quot;Psoriasis&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  page=&quot;Psoriasis&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;
│   │   page: Psoriasis
│   │   start: ~tc~ start ~/tc~
│   │   stop: ~tc~ end ~/tc~
│   children:
│   ├── TextNode
│   │   full_match: ``
│   │   inner_content: ``├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!VitaminDWiki – ((Vitiligo (spotty skin) and Vitamin D, UVB - many studies))`
│   inner_content: `VitaminDWiki – ((Vitiligo (spotty skin) and Vitamin D, UVB - many studies))`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki – `
│   │   inner_content: `VitaminDWiki – `
│   ├── LocalLinkNode
│   │   full_match: `((Vitiligo (spotty skin) and Vitamin D, UVB - many studies))`
│   │   inner_content: `Vitiligo (spotty skin) and Vitamin D, UVB - many studies`
│   │   page: `Vitiligo (spotty skin) and Vitamin D, UVB - many studies`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Vitiligo (spotty skin) and Vitamin D, UVB - many studies`
│   │   │   inner_content: `Vitiligo (spotty skin) and Vitamin D, UVB - many studies`├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!VitaminDWiki – ((Autoimmune)) category contains`
│   inner_content: `VitaminDWiki – ((Autoimmune)) category contains`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki – `
│   │   inner_content: `VitaminDWiki – `
│   ├── LocalLinkNode
│   │   full_match: `((Autoimmune))`
│   │   inner_content: `Autoimmune`
│   │   page: `Autoimmune`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Autoimmune`
│   │   │   inner_content: `Autoimmune`
│   ├── TextNode
│   │   full_match: ` category contains`
│   │   inner_content: ` category contains`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── IncludeNode
│   full_match: `{include page=&quot;Autoimmune&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  page=&quot;Autoimmune&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;
│   │   page: Autoimmune
│   │   start: ~tc~ start ~/tc~
│   │   stop: ~tc~ end ~/tc~
│   children:
│   ├── TextNode
│   │   full_match: ``
│   │   inner_content: ``├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!VitaminDWiki – ((Comparing High-dose vitamin D therapies)) has a summary table:`
│   inner_content: `VitaminDWiki – ((Comparing High-dose vitamin D therapies)) has a summary table:`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki – `
│   │   inner_content: `VitaminDWiki – `
│   ├── LocalLinkNode
│   │   full_match: `((Comparing High-dose vitamin D therapies))`
│   │   inner_content: `Comparing High-dose vitamin D therapies`
│   │   page: `Comparing High-dose vitamin D therapies`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Comparing High-dose vitamin D therapies`
│   │   │   inner_content: `Comparing High-dose vitamin D therapies`
│   ├── TextNode
│   │   full_match: ` has a summary table:`
│   │   inner_content: ` has a summary table:`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── IncludeNode
│   full_match: `{include page=&quot;Comparing High-dose vitamin D therapies&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  page=&quot;Comparing High-dose vitamin D therapies&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;
│   │   page: Comparing High-dose vitamin D therapies
│   │   start: ~tc~ start ~/tc~
│   │   stop: ~tc~ end ~/tc~
│   children:
│   ├── TextNode
│   │   full_match: ``
│   │   inner_content: ``

Original Tiki:
-------------
{DIV(class=&quot;lefth4&quot;)}{maketoc Title=&quot;&quot;}{DIV}
---
!!!!Safety Data in Patients with Autoimmune Diseases during Treatment with High Doses of Vitamin D3 According to the “Coimbra Protocol”
Nutrients 2022, 14(8), 1575; https://doi.org/10.3390/nu14081575
Ulrich Amon 1,*ORCID,Raul Yaguboglu 1,Madeleine Ennis 2, Michael F. Holick 3 ORCID and Julian Amon 1ORCID
*1 International Centre for Skin Diseases DermAllegra, __Coimbra Protocol Certified Center__, Am Markgrafenpark 6, 91224 Pommelsbrunn-Hohenstadt, Germany
*2 The Wellcome-Wolfson Institute for Experimental Medicine, Queens University of Belfast, Belfast BT7 1NN, UK
*3 Endocrinology, Diabetes, Nutrition &amp; Weight Management, Dept. of Medicine, Boston University School of Medicine, Boston, MA 02118, USA

{img type=&quot;attId&quot; attId=&quot;21487&quot; width=&quot;400&quot;}

{img type=&quot;attId&quot; attId=&quot;21488&quot; width=&quot;500&quot;} 

{img type=&quot;attId&quot; attId=&quot;21489&quot; width=&quot;500&quot;}
Background: In 2013, the group of Cicero Coimbra, Brazil, reported the clinical efficacy of high doses of vitamin D3 in patients suffering from autoimmune skin disorders (“Coimbra protocol”, CP). However, hypercalcemia and the subsequent impaired renal function may be major concerns raised against this protocol. 

Methods: We report for the first time for a broad spectrum of autoimmune diseases in 319 patients (mean age (±SD) 43.3 ± 14.6 years, 65.5% female, 34.5% male) safety data for high doses of orally applied vitamin D3 (treatment period: up to 3.5 years) accompanied by a strict low-calcium diet and regular daily fluid intake of at least 2.5 L. 

Results: Mean vitamin D3 dose was 35,291 ± 21,791 IU per day. The measurement of more than 6100 single relevant laboratory parameters showed all mean values (±SD) within the normal range for total serum calcium (2.4 ± 0.1 mmol/L), serum creatinine (0.8 ± 0.2 mg/dL), serum creatinine associated estimated GFR (92.5 ± 17.3 mL/min), serum cystatin C (0.88 ± 0.19 mg/L), serum TSH (1.8 ± 1 mIU/L), and for 24 h urinary calcium secretion (6.9 ± 3.3 mmol/24 h). We found a very weak relationship between the dosage of oral vitamin D3 and the subsequent calcium levels, both in serum and in urinary excretion over 24 h, respectively. 

Conclusions: Our data show the reliable safety of the CP in autoimmune patients under appropriate supervision by experienced physicians.
{FONT(size=&quot;17&quot;)}__{ATTACH(inline=&quot;1&quot; id=&quot;21486&quot; icon=&quot;1&quot;)}Download the PDF from VitaminDWiki {ATTACH}__{FONT}

{img type=&quot;attId&quot; attId=&quot;21490&quot; width=&quot;500&quot;}
75% had mutations in the genes encoding the enzymes CYP2R1 and CYP27B1 
 74% has 4+ mutations in nine different genes 
 5% had mutations in all genes investigated
----
!!!!Coimbra protocol appears to have not tried 8+ things
#Infrequent dosing, perhaps once every 3 days - a good way to get past the VDR
#Activation of Vitamin D receptors by Resveratrol and 14 other methods
#Glutathione etc, which activate many vitamin D genes
#Other forms of Vitamin D – which are more bioavailable – especially if poor gut
#The use of probiotics to improve the gut microbiome
#Water-soluble Vitamin D, Omega-3 - so that fat is not required concurrently 
#Loading dose to speedup the treatment by several months
#Plant-based Calcium for those who must have Calcium
---
!!!!VitaminDWiki – ((Overview MS and vitamin D)) contains 
{include page=&quot;Overview MS and vitamin D&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}
---
!!!!VitaminDWiki – ((Multiple Sclerosis and (lots of) Vitamin D - book by patient on Coimbra protocol - Feb 2016)) contains protocol description__     
{include page=&quot;Multiple Sclerosis and (lots of) Vitamin D - book by patient on Coimbra protocol - Feb 2016&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}
---
!!!!VitaminDWiki – ((Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019))
{include page=&quot;Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}
---
!!!!VitaminDWiki – ((Psoriasis)) category contains
{include page=&quot;Psoriasis&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}
---
!!!!VitaminDWiki – ((Vitiligo (spotty skin) and Vitamin D, UVB - many studies))
---
!!!!VitaminDWiki – ((Autoimmune)) category contains
{include page=&quot;Autoimmune&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}
---
!!!!VitaminDWiki – ((Comparing High-dose vitamin D therapies)) has a summary table:
{include page=&quot;Comparing High-dose vitamin D therapies&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}
</code>
</pre>
